Robeco Institutional Asset Management B.V. reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,599 shares of the medical instruments supplier's stock after selling 9,007 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Becton, Dickinson and Company were worth $9,300,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of BDX. Norges Bank acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $735,523,000. T. Rowe Price Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after buying an additional 3,219,317 shares in the last quarter. Kovitz Investment Group Partners LLC grew its stake in Becton, Dickinson and Company by 392.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after acquiring an additional 2,722,829 shares during the period. First Eagle Investment Management LLC increased its holdings in Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after acquiring an additional 1,057,879 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Becton, Dickinson and Company by 15.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after acquiring an additional 810,345 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Becton, Dickinson and Company Price Performance
Shares of NYSE:BDX traded up $4.02 during midday trading on Tuesday, hitting $176.27. The company had a trading volume of 359,759 shares, compared to its average volume of 2,030,739. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a market cap of $50.52 billion, a price-to-earnings ratio of 33.66, a price-to-earnings-growth ratio of 1.29 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The business's 50-day simple moving average is $176.04 and its 200-day simple moving average is $208.93.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the previous year, the firm earned $3.17 EPS. The company's quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were given a $1.04 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.36%. Becton, Dickinson and Company's payout ratio is 79.39%.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president owned 4,887 shares in the company, valued at $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on BDX shares. Barclays dropped their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a report on Thursday, May 1st. Wells Fargo & Company downgraded Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Finally, Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $219.22.
View Our Latest Research Report on BDX
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
